Biogen reported Phase 2 success for litifilimab, its anti-BDCA2 antibody program in systemic lupus erythematosus, framing it as a potential pillar within its immunology pipeline. The company said litifilimab improved skin lesions after 24 weeks, with 14.7% of patients reaching the relevant responder threshold. The update reinforces continued interest in type I interferon-pathway modulation and other innate immune targets in lupus, where heterogeneity often complicates trial outcomes. For Biogen, the key near-term question is whether Phase 3 can replicate skin efficacy and translate to broader clinical measures. Investors and partners will focus on safety, durability of response, and whether the program’s patient selection strategy can tighten benefit signals as the asset progresses.